Endothelial envelopment drug carriers

• US 5,108,759 A
• Filed: 12/08/1989
• Issued: 04/28/1992
• Est. Priority Date: 04/01/1987
• Status: Expired due to Fees

• Current Assignee: Access Pharmaceuticals Inc.
• Original Assignee: David F. Ranney
• Inventors: Ranney, David F.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): AZPURU, CARLOS A
• Application Number:
  US07/448,121
• Time in Patent Office: 872 Days
• Field of Search: 424/7.1, 424/9, 424/85.2, 424/450, 424/460, 424/461, 424/463, 424/469, 424/488, 424/499, 428/402.2, 428/402.24, 436/829, 514/963, 514/965
• US Class Current: 424/493
• CPC Class Codes: A61K 47/61 the organic macromolecular compound being a polysaccharide or a derivative thereof
• CPC Class Codes: A61K 47/69 the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• CPC Class Codes: A61K 9/1652 Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin homeopathic globules A61K9/1623
• CPC Class Codes: A61K 9/167 with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface with further drug-free outer coating A61K9/5073
• CPC Class Codes: A61K 9/5036 Polysaccharides, e.g. gums, alginate; Cyclodextrin
• CPC Class Codes: A61K 9/5146 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
• CPC Class Codes: A61K 9/5161 Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
• CPC Class Codes: Y10S 436/829 Liposomes, e.g. encapsulation
• CPC Class Codes: Y10T 428/2984 Microcapsule with fluid core [includes liposome]
• CPC Class Codes: Y10T 428/2989 Microcapsule with solid core [includes liposome]

Abstract

This application describes the preparation and in vivo testing of surface coatings and matrix materials, which when applied to or caused to comprise the carriers for drugs and diagnostic agents, and administered in a fashion that allows efficient vascular access, causes the carriers to recognize determinants present or normal or focally diseased endothelium, and induces the following in vivo effects: 1) rapid, partial or total endothelial envelopment of the drug (diagnostic) carrier; 2) sequestration of the carrier and protecting entrapped agent from blood vascular clearance at an early time (2 minutes) when the endothelial pocket which envelops the carrier still invaginates into the vascular compartment; 3) acceleration of the carrier'"'"'s transport across or through the vascular endothelium and/or subendothelial structures into the tissue compartment (interstitium); and 4) improvement of the efficiency with which the drug (or diagnostic) carrier migrates across the endothelium, or epi-endothelial or subendothelial barriers, such that a lower total drug dose is required to obtain the desired effect relative to that required for standard agents.

Claims

1. A composition comprising a multivalent binding agent surface which binds determinants of endothelial or epithelial cells;

wherein the composition is a microsphere, microaggregate, or macromolecule less than about 250 micrometers in size, and has a matrix capable of containing a drug or diagnostic agent at a content of at least 12% (w/w); and

wherein the multivalent binding agent surface consists of carbohydrate, oligosaccharide, monosaccharide, negatively charged polysaccharide, negatively charged oligosaccharide, dextran sulfate, glycosaminoglycan, heparin, heparin fragment, synthetic heparin analogue, heparan sulfate, dermatan sulfate, chondroitin sulfate, hyaluronic acid; and

which induces rapid partial or total envelopment of said composition by endothelial or epithelial cells and facilitated migration across said cells into proximal tissues.

4. The composition of claim 1 defined further as consisting of microparticles or microaggregates coated with heparins which bind to complementary substances present on endothelium or epithelium, said complementary substances including heparan sulfates and antithrombin III.

5. The composition of claim 1 wherein the multivalent binding agent surface coating is reversibly blocked by a chemical moiety that renders the multivalent binding agent initially covert and wherein the reversibly blocking chemical moiety is susceptible to release by triggering agents including lowered pH, altered temperature, contact with normal or abnormal endothelia or epithelia, altered enzyme levels, degradative enzymes, radiofrequency energy, ultrasound, magnetism or electricity.

6. The composition of claim 1 wherein the drug or diagnostic agent is a drug active against microorganisms.

7. The composition of claim 6 wherein the drug or diagnostic agent is an antifungal agent.

8. The composition of claim 1 wherein the drug or diagnostic agent is a drug active against tumor cells.

9. The composition of claim 1 wherein the drug or diagnostic agent is a drug active in treating biological lesions which involve activated or diseased endothelium or subendothelial molecules or structures.

10. The composition of claim 1 wherein the carrier comprises one or more of macromolecules, microaggregates, microparticles, microspheres, and microemulsions.

11. The composition of claim 1 wherein the multivalent binding agent surface binds to laminin, collagen, fibronectin or fibronectin fragments.

2. A composition comprising a multivalent binding agent surface which binds determinants of endothelial or epithelial cells;

wherein the composition is a microsphere, microaggregate, or macromolecule less than about 250 micrometers in size, and has a matrix capable of containing a drug or diagnostic agent at a content of at least 12% (w/w); and

wherein the multivalent binding agent is a heparin, a heparin fragment, or synthetic heparin analogue, which induces rapid partial or total envelopment of said composition by endothelial or epithelial cells and facilitated migration across said cells into proximal tissues.

3. A composition comprising a multivalent binding agent surface which binds determinants of endothelial or epithelial cells;

wherein the composition is a microsphere, microaggregate, or macromolecule less than about 250 micrometers in size, and has a matrix capable of containing a drug or diagnostic agent at a content of at least 12% (w/w); and

wherein the multivalent binding agent consists essentially of heparin, heparin fragment, synthetic heparin analogue, heparan sulfate, dermatan sulfate, chondroitin sulfate, hyaluronic acid or dextran sulfate, which induces rapid partial or total envelopment of said composition by endothelial or epithelial cells and facilitated migration across said cells into proximal tissues.